Company Analysis
Sign in

Oculis Holding AG (OCS)

Nasdaq: OCS · Pharmaceutical Preparations · Zug, CH · filing with the SEC since 2022
Full chart Alerts Compare
Grade5.1
◀ Past 4.7● Present 5.3▶ Future 5.3
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In thousands of Swiss francs (CHF), as filed; per-share figures in Swiss francs; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Report filedMar 4, 2026Mar 11, 2025Mar 19, 2024Mar 28, 2023··
For lenders
Net interest income···1262110
Research and development57,08552,08329,24722,2249,5689,337
General and administrative25,78621,80717,48711,0644,6243,992
Total operating expenses82,87173,89081,59733,28814,19213,329
Operating income-81,672-73,204-80,714-32,376-13,232-12,336
Finance costs8336391,3156,4425,1202,628
Finance income1,7702,1681,4291262110
Net finance income (costs)-17,471-12,733-7,981-6,267-5,292-2,455
Income before income taxes-99,143-85,937-88,695-38,643-18,524-14,790
Income tax expense-186-160107552783
Net income-98,957-85,777-88,802-38,698-18,552-14,873
Earnings per share, basic-1.89-2.12-2.97-11.32r-5.84r-5.77
Earnings per share, diluted-1.89-2.12-2.97-11.32r-5.84r-5.77
Weighted average shares, basic52,243,10040,406,55129,899,6512,989,4342,777,5892,579,385
Weighted average shares, diluted52,243,10040,406,55129,899,6512,989,4342,777,5892,579,385
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Net interest income interest earned less interest paidifrs-full:InterestRevenueExpense
Research and development spent on inventing what it sells nextifrs-full:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfifrs-full:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherifrs-full:OperatingExpense
Operating income profit from running the business, before interest and taxifrs-full:ProfitLossFromOperatingActivities
Finance costs what its borrowing costifrs-full:FinanceCosts
Finance income what its cash and investments earnedifrs-full:FinanceIncome
Net finance income (costs) interest earned less interest paid, outside the businessifrs-full:FinanceIncomeCost
Income before income taxes profit before taxifrs-full:ProfitLossBeforeTax
Income tax expense tax charged on the period's profitifrs-full:IncomeTaxExpenseContinuingOperations
Net income the whole group's profit, minority holders' share includedifrs-full:ProfitLoss
Earnings per share, basic net income per share outstandingifrs-full:BasicEarningsLossPerShare
Earnings per share, diluted net income per share, counting every share that could be issuedifrs-full:DilutedEarningsLossPerShare
Weighted average shares, basic the average count of shares outstandingifrs-full:WeightedAverageShares
Weighted average shares, diluted the average count with every share that could be issuedifrs-full:AdjustedWeightedAverageShares
SI Assistanton OCS · research, not advice